Shorts have nothing to do with it. The news while showing progress isn't enough to convince the market that its worth Buying.Sellers agree.
To get to phase 3 they need to submit data, have the FDA approve its sufficient with no further questions, review it if none, if approved to take the next step , enroll, begin trials, conclude trials, and IF they're successful, submit to the FDA, they review, assuming no further questions approve or disapprove. That's a year or more before anything is known. The market hasn't the patience for that. Competition is fierce and will have something to go with by year end or the 1st quarter 2021.